Media coverage about Evoke Pharma (NASDAQ:EVOK) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evoke Pharma earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.8119425767797 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern’s analysis:
Several research firms have issued reports on EVOK. HC Wainwright set a $9.00 price target on Evoke Pharma and gave the company a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Thursday, March 8th. Finally, B. Riley reaffirmed a “buy” rating and issued a $5.00 price target (down previously from $10.00) on shares of Evoke Pharma in a report on Thursday, March 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $7.71.
NASDAQ EVOK opened at $2.14 on Friday. Evoke Pharma has a 1 year low of $1.85 and a 1 year high of $4.09.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.21. research analysts anticipate that Evoke Pharma will post 0.11 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-evoke-pharma-evok-stock-price.html.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.